This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
=== Nexon === In August 2014, Nexon announced Counter-Strike Nexon: Zombies, a free-to-play, zombie-themed spin-off, developed on the GoldSrc game engine. On September 23, 2014, an open beta was released on Steam. The game launched on October 7, 2014, featuring 50 maps and 20 game modes. The game features both player versus player modes such as team deathmatch, hostage rescue, and bomb defusal, alongside player versus environment modes such as cooperative campaign missions and base defending. Reception from critics was generally negative, with criticism aimed at the game's poor user interface, microtransactions, and dated graphics. On October 30, 2019, Counter-Strike Nexon: Zombies was renamed to Counter-Strike Nexon: Studio. On August 21, 2024, Counter-Strike Nexon: Studio was renamed to Counter-Strike Nexon. The game is set to be shut-down on September 30, 2026.
Regulatory agencies, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), have established approval pathways to ensure biosimilar insulins meet the same quality, safety, and efficacy standards as reference products.
==== Autism Spectrum Disorders (ASD) ==== Alterations in AMPAR trafficking have been implicated in ASD. Studies indicate that dysregulation of proteins involved in AMPAR trafficking, such as CYFIP1, leads to synaptic dysfunction associated with autism-like behaviors.
Sources: en.wikipedia.org
High-power LEDs (HP-LEDs) or high-output LEDs (HO-LEDs) can be driven at currents from hundreds of mA to more than an ampere, compared with the tens of mA for other LEDs. Some can emit over a thousand lumens. LED power densities up to 300 W/cm2 have been achieved. Since overheating is destructive, the HP-LEDs must be mounted on a heat sink to allow for heat dissipation. If the heat from an HP-LED is not removed, the device fails in seconds. One HP-LED can often replace an incandescent bulb in a flashlight, or be set in an array to form a powerful LED lamp. Some HP-LEDs in this category are the Nichia 19 series, Lumileds Rebel Led, Osram Opto Semiconductors Golden Dragon, and Cree X-lamp. As of September 2009, some HP-LEDs manufactured by Cree exceed 105 lm/W. Examples for Haitz's law—which predicts an exponential rise in light output and efficacy of LEDs over time—are the CREE XP-G series LED, which achieved 105 lm/W in 2009 and the Nichia 19 series with a typical efficacy of 140 lm/W, released in 2010.
Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.
== Types == Fomentations – heated poultices – may be used to promote blood circulation to an affected area; these may be unmedicated. Cold poultices are sometimes used. An example is the use of cabbage leaves to reduce breast engorgement in breastfeeding mothers. The leaves are applied directly to the breast, often simply held in place by a bra. Evidence for effectiveness as a treatment is weak: cabbage poultices are about as effective as the frequent, unrestricted feeding of the infant; they have no effect on the rate of progression to mastitis. There is some slight evidence that cabbage poultices reduce the pain of engorgement.
Sources: en.wikipedia.org
=== NNPC Bags Transparency Award === The efforts of the Mallam Mele Kyari-led Management of the Nigerian National Petroleum Corporation (NNPC) to entrench the culture of transparency in the system have begun to receive recognition with the Corporation named as the “Government Agency of the Year 2020 (Transparency)” by the New Telegraph.
The original Counter-Strike has been played in competitive tournaments since 2000, with the first major event taking place at the Cyberathlete Professional League (CPL) Winter Championship in 2001. The CPL announced a transition from Quake III Arena to Counter-Strike for the Winter Championship. Prior to this, the 2000 Babbage's event featured a Counter-Strike competition sponsored by Kärna, the parent company of Razer, offering a $15,000 prize pool. However, Kärna experienced financial difficulties, leading to delays in prize payouts. On March 14, 2001, the CPL issued a statement confirming that alternative arrangements would be made if the payments were not received by April 2, 2001.
For coal samples originating near the Equator, δD is around −50‰, while for those originating from polar regions, δD is around −150‰. This δD trend along latitude is consistent meteoric water trend and thus is an evidence that coals can preserve much of the original signals. There are two types of approach to study the alteration of DHRs of kerogen during catagenesis: (1) laboratory incubation of organic matter that enables mechanistic study with controlled experiments; (2) natural sample measurement that provides information of combined effects over geologic timescales. The complex composition and chemistry of kerogen complicates the results. Nevertheless, most research on HIC of kerogen show D enrichment with increasing maturity. Type II kerogen (marine derived) from New Albany Shale is reported to have δD rise from −120‰ to −70‰ as vitrinite reflectance increase from 0.3% to 1.5%. Two main mechanisms have been proposed for enrichment. One of them is kinetic fractionation during hydrocarbon generation while the other is isotopic exchange with surrounding water. Anhydrous incubation experiments have shown that the products are generally more D-depleted than their precursors, causing enrichment in residual kerogen. Schimmelmann et al. studied the relationship between terrestrially derived oil and their source rock kerogens from four Australian Basins. They found that on average the oil is depleted to corresponding kerogen by 23‰. Hydrous incubation experiments suggest that 36–79% of bulk organic hydrogen may come from water at moderate maturity.
== Reactions == Hippuric acid is readily hydrolysed by hot caustic alkalis to benzoic acid and glycine. Nitrous acid converts it into benzoyl glycolic acid, C6H5C(=O)OCH2CO2H. Its ethyl ester reacts with hydrazine to form hippuryl hydrazine, C6H5CONHCH2CONHNH2, which was used by Theodor Curtius for the preparation of hydrazoic acid. Hippuric acid has also been used in Erlenmeyer–Plöchl synthesis of phenylalanine and other amino acids, the reaction proceeding via an oxazolone or "azlactone" intermediate.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.